A shot in the arm for Isis

Since it was founded in 1989, Isis Pharmaceuticals Inc. has gotten one drug on the market, Vitravene fomivirsen, which was launched in 1998 to treat cytomegalovirus retinitis infections in AIDS patients, but the indication is vanishingly small. In the interim, the company has persevered through multiple clinical failures and a couple of restructurings. Now ISIS thinks it finally has

Read the full 596 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE